|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03347 TIGERMED
Nominal 
33.550 +1.150 (+3.549%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 3,358,244 | -9.502% | 3,710,850 | 3,594,209 | 2,056,375 | 1,451,994 |
| Cost of Sales | -- | -- | -- | (2,175,881) | (1,089,456) | (753,880) |
| Gross Profit | -- | -- | -- | 1,418,328 | 966,919 | 698,114 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (134,487) | -- | 499,980 | (28,411) | (10,252) | (5,811) | |
| Profit / (Loss) on Disposal | 1,490 | -- | (6) | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | (590) | |
| Share of Results of Asso. & JCEs | 44,095 | -30.803% | 63,724 | 35,556 | 723 | (4,269) | |
| Profit / (Loss) before Taxation | 690,093 | -56.846% | 1,599,145 | 1,479,865 | 1,697,716 | 1,139,398 | |
| Taxation | (132,514) | -30.641% | (191,055) | (162,239) | (103,533) | (90,400) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (64,730) | 227.696% | (19,753) | (125,622) | (334,269) | (37,121) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 492,849 | -64.501% | 1,388,337 | 1,192,004 | 1,259,914 | 1,011,877 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (16,109) | -77.004% | (70,049) | (82,583) | (126,419) | 11,375 |
| Depreciation & Amortisation | 180,372 | 11.273% | 162,099 | 122,774 | 88,609 | 70,832 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 57.000 | -64.596% | 161.000 | 138.000 | 145.000 | 136.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 24.007 | -- | -- | 21.441 | 19.577 | -- |
| Remarks: | Real time quote last updated: 27/11/2024 12:15 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 492,849 |
| %Change | -64.501% |
| EPS / (LPS) | RMB 0.570 |
| NBV Per Share (¥) | RMB 24.007 |